Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Authors
Keywords
T cells, Cancer treatment, Cytotoxic T cells, Pancreatic cancer, Regulatory T cells, Toxicity, NK cells, Surgical and invasive medical procedures
Journal
PLoS One
Volume 12, Issue 1, Pages e0169736
Publisher
Public Library of Science (PLoS)
Online
2017-01-19
DOI
10.1371/journal.pone.0169736
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic Intraductal Papillary Mucinous Neoplasm - Where Is the Challenge?
- (2015) Stefan Fritz et al. DIGESTIVE DISEASES
- A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
- (2015) Gustav J. Ullenhag et al. PLoS One
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial
- (2013) Jeffrey Infante et al. CANCER BIOLOGY & THERAPY
- Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy
- (2013) Alexandr V. Bazhin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
- (2013) Y. Homma et al. Clinical & Translational Oncology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
- (2011) Bang-Ning Lee et al. CANCER
- Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
- (2011) A. Maraveyas et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer
- (2011) Tomohisa Yamamoto et al. PANCREAS
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer
- (2010) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
- (2009) M Lioznov et al. BONE MARROW TRANSPLANTATION
- Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
- (2009) M. K. Srivastava et al. CANCER RESEARCH
- Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
- (2009) Atsuko Soeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
- (2008) Fariba Mozaffari et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
- (2008) Sharon L. Sanborn et al. INVESTIGATIONAL NEW DRUGS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started